Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | PKLR | P30613 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 3/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30970378 | 1.00 | PRKCI (0.37) | PRKCIPKLRDYRK1ADYRK2DYRK1B | |
| SCHEMBL31015934 | 0.89 | CTNNB1 (0.38) | PRKCIDYRK1ADYRK1BMTNR1AMTNR1B | |
| SCHEMBL10158236 | 0.89 | CTNNB1 (0.38) | PRKCIDYRK1ADYRK1BMTNR1AMTNR1B | |
| SCHEMBL1701459 | 0.83 | AHR (0.42) | PRKCIDYRK1ADYRK2DYRK1BHDAC3 | |
| SCHEMBL13100028 | 0.83 | PKLR (0.43) | PRKCIPKLRDYRK1ADYRK2DYRK1B | |
| SCHEMBL25209057 | 0.81 | SMN1; SMN2 (0.39) | PRKCIDYRK1ADYRK1BRAB9ANPC1 | |
| SCHEMBL31015951 | 0.81 | SMN1; SMN2 (0.39) | PRKCIDYRK1ADYRK1BRAB9ANPC1 | |
| SCHEMBL23618815 | 0.80 | DYRK1A (0.41) | PRKCIPKLRDYRK1ADYRK2DYRK1B | |
| SCHEMBL1702363 | 0.79 | MAPT (0.42) | RAB9ANPC1MAPTKDM4E | |
| SCHEMBL3463711 | 0.77 | PRKCI (0.35) | PRKCIDYRK1ADYRK2DYRK1BHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024115641-A1 | NONCOVALENT KEAP1-NRF2 SMALL-MOLECULE INHIBITORS | UNIVERSITY OF COPENHAGEN (DK) | 2024-06-06 | — | — | WO | disclosed |
| US-11905248-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2020-10-08 | — | — | US | disclosed |
| US-10703722-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| EP-2563776-B1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC (US) | 2016-06-08 | — | — | EP | disclosed |
| EP-2563776-B1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20150322012-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-11-12 | — | — | US | disclosed |
| US-20150322012-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-11-12 | — | — | US | disclosed |
| US-9120751-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| EP-1373192-A1 | N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD | Pfizer Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-6660756-B2 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-12-09 | — | — | US | disclosed |
| US-6642230-B2 | Administering novel compounds which bind to corticotropin releasing factor receptors, thereby altering anxiogenic effects of CRF secretion | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-20030114468-A1 | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders | WILDE RICHARD GERALD (US) | 2003-06-19 | — | — | US | disclosed |
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2002079143-A1 | N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
| US-6362180-B1 | ANTAGONIST TO CORTICOTROPIN RELEASING FACTOR | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-03-26 | — | — | US | disclosed |
| US-6143743-A | TREATMENT OF NERVOUS SYSTEM DISORDERS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-11-07 | — | — | US | disclosed |
| EP-0994877-A1 | IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Du Pont Pharmaceuticals Company (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999001454-A1 | IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322012-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | PRKCI 473/4885PKLR 3797/4885DYRK1A 3712/4885 |
| US-10703722-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | PRKCI 473/4885PKLR 3797/4885DYRK1A 3712/4885 |
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PREP, ENGASE, ENPEP | PRKCI 4329/4885PKLR 2104/4885DYRK1A 4437/4885 |
| US-20030114468-A1 | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders | CRH, CRHR1, CRHR2 | PRKCI 3189/4885PKLR 1605/4885DYRK1A 4135/4885 |
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | PRKCI 473/4885PKLR 3797/4885DYRK1A 3712/4885 |
| US-11905248-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | PRKCI 473/4885PKLR 3797/4885DYRK1A 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.